Prostate Cancer Diagnostics Market Size, Share, Growth, and Industry Analysis, By Type (PSA Tests,CTC Tests,Immunohistochemistry,PCA3 Tests,Others), By Application (Hospital Associated Labs,Independent Diagnostic Laboratories,Cancer Research Institutes,Others), Regional Insights and Forecast to 2035

Prostate Cancer Diagnostics Market Overview

The global Prostate Cancer Diagnostics Market in terms of revenue was estimated to be worth USD 7470.57 Million in 2026 and is poised to reach USD 27617.18 Million by 2035, growing at a CAGR of 15.64% from 2026 to 2035.

Global prostate cancer incidence is around 1 200 000 new cases annually, with mortality over 350 000 deaths per year and approximately 12 % lifetime risk in men. North America held about 46 % share of diagnostic activity in 2024, while confirmatory tests accounted for roughly 67 % share of test volumes globally and prostatic adenocarcinoma drove over 91 % of diagnoses. PSA testing comprised approximately 45 % of all test type usage in 2022, while diagnostic imaging and biomarkers such as PCA3 and CTC tests accounted for remaining 55 % usage volumes.

In the USA in 2023 approximately 299 010 new prostate cancer cases were diagnosed and approximately 34 700 deaths occurred, representing about 1 in 8 men lifetime risk and 1 in 40 mortality. U.S. prostate cancer diagnostics accounted for roughly USD 2.96 billion worth of diagnostic testing volumes in 2023, representing around 33 % of North American test volumes. North America as a whole represented 46 % share of diagnostic market activity. Confirmatory tests represented approximately 67 % of Canadian and U.S. test volume combined in 2023. Prostatic adenocarcinoma comprised more than 95 % of cases detected via tests in USA

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Driver: 46 % of global diagnostic test volume driven by PSA testing uptake.
• Major Market Restraint: 34 700 annual deaths correspond to nearly 29 % of diagnosed cases in USA indicating late detection challenges.
• Emerging Trends: 12 % of tests now use CTC or PCA3 assays instead of standard PSA in 2024.
• Regional Leadership: North America held 46 % share of global diagnostic activity in 2024.
• Competitive Landscape: Top two companies (Abbott, Myriad Genetics) combined hold about 20 % share of U.S. test kit distribution.
• Market Segmentation: Confirmatory tests comprise 67 % of test volume; preliminary screening tests 33 %.
• Recent Development: In 2023, prostatic adenocarcinoma represented over 95 % of diagnoses globally.

Prostate Cancer Diagnostics Market Trends

The Prostate Cancer Diagnostics Market Report shows that PSA screening remains predominant, accounting for roughly 45 % of all diagnostic procedures as of 2022 with confirmatory testing uptake at about 67 % of overall testing volumes. Liquid biopsy via CTC or PCA3 now contributes approximately 12 % of diagnostic volumes in 2024. Imaging techniques, including mpMRI and AI‑enabled platforms, represent around 20 % of test usage in advanced diagnostic settings. US hospitals perform about 60 % of confirmatory tests, while independent diagnostic labs account for around 25 %. In the USA alone, approximately 299 010 men were newly diagnosed in 2023 and roughly 34 700 deaths were recorded, which underscores increasing screening demand.

Prostatic adenocarcinoma comprises over 95 % of detected prostate cancers. Hospital associated labs conduct around 65 % of total application end‑use volume, with cancer research institutions at 10 %. Growth in Asia‑Pacific testing volume reached nearly 22 % of global volume in 2024. Emerging trend of at‑home PSA testing kits accounts for about 5 % of total screening in North America. The Prostate Cancer Diagnostics Market Analysis highlights increasing adoption of genomic PCA3 in 8 % of cases and immunohistochemistry in 10 % of cases globally. This Prostate Cancer Diagnostics Industry Analysis underscores trend toward non‑invasive biomarker diagnostics, AI‑based imaging, and increased usage of confirmatory biopsy reduction protocols in 15 % of screening pathways.

Prostate Cancer Diagnostics Market Dynamics

DRIVER

"Rising demand for early detection technologies"

Rising demand for early detection technologies such as PSA, PCA3, CTC and imaging is driving growth. In 2023, preliminary screening tests represented approximately 33 % of test volume globally, and confirmatory tests represented 67 %. In USA, approximately 299 010 men were diagnosed in 2023 and about 34 700 deaths occurred, pushing demand for accurate diagnostics. Liquid biopsy applications grew to about 12 % of testing volumes in 2024, while AI‑enabled imaging constituted nearly 20 %. Hospital associated labs handled around 65 % of end‑use volume. Asia‑Pacific accounted for approximately 22 % of global volume in 2024.

RESTRAINT

"Limited access and high test costs"

In developing regions, diagnostic access accounts for less than 5 % of global test volume in Latin America and Middle East & Africa combined. Test costs for PCA3 or liquid biopsy remain approximately 30 % higher than standard PSA in many hospitals. Government screening initiatives in Asia‑Pacific cover only around 40 % of at‑risk male population aged above 50. Confirmatory biopsy procedures still comprise 67 % of volume, indicating reluctance to adopt newer assays, which make up only about 33 %.

OPPORTUNITY

"Expansion of biomarker and AI innovations"

In 2024, PCA3 and CTC-based testing accounted for around 12 % of test volumes globally, leaving about 88 % for standard PSA and imaging methods. AI‑based imaging platforms were adopted in roughly 20 % of advanced diagnostic centers. Asia‑Pacific region contributed approximately 22 % of global volume, suggesting room for growth. Hospital associated labs currently handle 65 % of application volume; independent labs and research institutes combined represent about 35 % offering expansion opportunities. The shift from confirmatory biopsy (67 %) toward non‑invasive liquid biopsy (12 %) and immunohistochemistry (10 %) could reduce biopsy procedures by 15 %.

CHALLENGE

"Regulatory hurdles and infrastructure gaps"

Only about 40 % of Asia‑Pacific countries have reimbursement for PCA3 or CTC tests. In Middle East & Africa region, test volume is under 3 % of global total. Confirmatory biopsy remains mandatory in about 67 % of cases, slowing adoption of new methodologies. Infrastructure limitations mean that independent diagnostic labs represent only 25 % of US end‑use share. Government health centres in developing markets cover only 40 % of population over age 50 for screening programs. Integration of AI platforms reaches just 20 % of diagnostic centers.

Prostate Cancer Diagnostics Market Segmentation

By Test Type, diagnostic segmentation splits between PSA Tests, CTC Tests, Immunohistochemistry, PCA3 Tests, and Others. PSA Tests accounted for approximately 45 % of test volumes in 2022; CTC and PCA3 combined for around 12 %; Immunohistochemistry accounted for roughly 10 %; others imaging modalities made up about 33 %. By Application, segmentation includes Hospital Associated Labs (approximately 65 % of volume), Independent Diagnostic Laboratories (~25 %), Cancer Research Institutes (~10 %), and Others (approximately 5 %). Hospital associated labs dominate test handling, while independent labs and research institutes serve a quarter and a tenth of application share respectively.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

PSA Tests: accounted for roughly 45 % of diagnostic test volume globally in 2022. In North America, PSA testing represented approximately 50 % of preliminary screening volumes in USA. In Europe, PSA accounted for around 40 % of total tests. Asia‑Pacific regions had lower PSA share at about 35 % in 2024 due to emerging biomarker adoption. PSA is used in routine screening programs in Medicare‑eligible men aged over 50, representing around 46 % share in USA screening activities. Confirmatory PSA retesting rounds comprised nearly 30 % of repeated testing cycles. PSA test usage remains highest within hospital‑based labs (~55 % of PSA volume), while independent labs contribute around 20 %.

Global PSA Tests segment size is USD 1 820 million in 2025, with approximately 28 % share, growing at 15.64 % CAGR to 2034.

Top 5 Major Dominant Countries in the PSA Tests Segment

• United States: PSA Tests segment size ~USD 720 million with ~40 % share, 15.64 % CAGR through 2034.
• Germany: PSA Tests size ~USD 220 million with ~12 % share, 15.64 % CAGR through projection period.
• United Kingdom: PSA Tests size ~USD 160 million with ~9 % share, 15.64 % CAGR through 2034.
• Japan: PSA Tests size ~USD 140 million with ~8 % share, CAGR 15.64 % to 2034.
• China: PSA Tests size ~USD 120 million with ~7 % share, 15.64 % CAGR through 2034.

CTC Tests: made up around 7 % of global prostate cancer diagnostic test volume in 2024, while PCA3 tests added another 5 %, totalling approximately 12 % combined. In North America, CTC testing accounted for about 8 % of diagnostic volume in 2023. In Europe, adoption reached roughly 6 %. Asia‑Pacific regions saw CTC usage at around 4 % due to limited infrastructure. Hospital labs conducted about 70 % of CTC tests, independent labs around 20 %, and research institutes about 10 %. CTC testing is often used in treatment monitoring rather than screening, representing approximately 15 % of monitoring test volume.

Global PSA Tests segment size is USD 1 820 million in 2025, with approximately 28 % share, growing at 15.64 % CAGR to 2034.

Top 5 Major Dominant Countries in the PSA Tests Segment

• United States: PSA Tests segment size ~USD 720 million with ~40 % share, 15.64 % CAGR through 2034.
• Germany: PSA Tests size ~USD 220 million with ~12 % share, 15.64 % CAGR through projection period.
• United Kingdom: PSA Tests size ~USD 160 million with ~9 % share, 15.64 % CAGR through 2034.
• Japan: PSA Tests size ~USD 140 million with ~8 % share, CAGR 15.64 % to 2034.
• China: PSA Tests size ~USD 120 million with ~7 % share, 15.64 % CAGR through 2034.

Immunohistochemistry: tests comprised approximately 10 % of global prostate cancer diagnostic volume in 2024. In USA hospital labs, IHC accounted for near 12 % of test mix. Europe contributed around 9 % share. Asia‑Pacific adoption was approximately 5 %. IHC is primarily used post‑biopsy to characterize tumour markers, accounting for around 20 % of all biopsy‑related diagnostics. Hospital associated labs carry out about 75 % of IHC testing; independent diagnostic labs cover roughly 15 %, with cancer research institutes at 10 %. IHC usage is growing in research settings by about 5 % annual increase in test order volumes.

Global Immunohistochemistry segment size is USD 480 million in 2025, with ~7 % share, growing at 15.64 % CAGR to 2034.

Top 5 Major Dominant Countries in the Immunohistochemistry Segment

• United States: IHC size ~USD 200 million with ~42 % share, CAGR 15.64 % by 2034.
• Germany: IHC size ~USD 60 million with ~13 % share, CAGR 15.64 % through 2034.
• United Kingdom: IHC size ~USD 45 million with ~9 % share, 15.64 % CAGR to 2034.
• Japan: IHC size ~USD 42 million with ~8 % share, CAGR 15.64 % to 2034.
• China: IHC size ~USD 36 million with ~7 % share, CAGR 15.64 % through 2034.

PCA3 Tests: accounted for approximately 5 % of global diagnostic test volume in 2024, combined with CTC to form 12 %. In the USA, PCA3 comprised around 6 % of diagnostic protocols. Europe share was about 5 %, Asia‑Pacific near 3 %. PCA3 is used to reduce unnecessary biopsies, and where utilised, it reduced biopsy procedures by roughly 15 %. Hospital labs conducted about 70 % of PCA3 testing; independent labs handled ~20 %; research institutes ~10 %. PCA3 uptake is strongest in North America, representing 6 % of diagnostic mix versus 3 % in Asia‑Pacific, reflecting infrastructure disparities.

Global PCA3 Tests segment size is USD 500 million in 2025, with ~8 % share, growing at 15.64 % CAGR to 2034.

Top 5 Major Dominant Countries in the PCA3 Tests Segment

• United States: PCA3 Tests size ~USD 210 million with ~42 % share, CAGR 15.64 % through 2034.
• Germany: PCA3 size ~USD 65 million with ~13 % share, 15.64 % CAGR to 2034.
• United Kingdom: PCA3 size ~USD 50 million with ~10 % share, CAGR 15.64 % to 2034.
• Japan: PCA3 size ~USD 44 million with ~9 % share, 15.64 % CAGR through 2034.
• China: PCA3 size ~USD 39 million with ~8 % share, CAGR 15.64 % to 2034.

Others: diagnostic types including advanced imaging, mpMRI, digital pathology, and emerging assays accounted for approximately 33 % of test volume globally in 2024. In North America, others represented around 30 %. Europe contributed approximately 35 %, Asia‑Pacific about 45 % due to imaging focus rather than biomarker tests. Hospital associated labs conducted nearly 60 % of these procedures, independent labs 25 %, cancer research institutes 15 %. Other tests include ultrasound Doppler and AI‑based imaging which reduced biopsy counts by about 10 %. These modalities are increasingly used for localization before biopsy in roughly 20 % of suspected cases.

Global Others segment size is USD 2 080 million in 2025, with ~32 % share, growing at 15.64 % CAGR to 2034.

Top 5 Major Dominant Countries in the Others Segment

• United States: Others segment size ~USD 850 million with ~41 % share, CAGR 15.64 % to 2034.
• Germany: Others size ~USD 260 million with ~12 % share, CAGR 15.64 % through 2034.
• United Kingdom: Others size ~USD 180 million with ~9 % share, 15.64 % CAGR to 2034.
• Japan: Others size ~USD 170 million with ~8 % share, 15.64 % CAGR to 2034.
• China: Others size ~USD 150 million with ~7 % share, CAGR 15.64 % to 2034.

BY APPLICATION

Hospital associated labs: handled approximately 65 % of total prostate cancer diagnostic volume in 2023 globally. In North America they accounted for around 70 % of test volume; Europe about 60 %; Asia‑Pacific around 55 %. Confirmatory tests in hospitals represent approximately 67 % of application volume. PSA screening in hospital labs forms roughly 55 % of hospital activity. CTC and PCA3 testing together represent about 8 % of hospital lab volume. IHC and imaging in hospital labs account for 12 % and 30 % respectively. Hospital based labs conduct approximately 65 % of biopsy‑associated diagnostics, supporting early detection and treatment pathways.

Hospital Associated Labs segment size is USD 3 300 million in 2025, with ~51 % share, growing at 15.64 % CAGR to 2034.

Top 5 Major Dominant Countries in the Hospital Associated Labs Application

• United States: Hospital labs size ~USD 1 350 million with ~41 % share, CAGR 15.64 % by 2034.
• Germany: Hospital labs size ~USD 465 million with ~14 % share, CAGR 15.64 % to 2034.
• United Kingdom: Size ~USD 330 million with ~10 % share, CAGR 15.64 % through 2034.
• Japan: Size ~USD 315 million with ~10 % share, 15.64 % CAGR to 2034.
• China: Size ~USD 300 million with ~9 % share, CAGR 15.64 % through 2034.

Independent Diagnostic Laboratories: accounted for approximately 25 % of prostate cancer test volume globally in 2023. In North America, independence labs cover around 20 %; Europe 25 %; Asia‑Pacific 30 %. Independent labs perform approximately 33 % of preliminary screening tests, and about 15 % of confirmatory tests. PSA tests in independent labs represent roughly 20 % of their volume; CTC and PCA3 combined about 4 %; IHC about 15 %; others imaging about 61 %. Independent labs contribute significant volume in outpatient settings and mobile testing units, accounting for around 30 % of at‑home or outside hospital screening events.

Independent Laboratories segment size is USD 1 290 million in 2025, with ~20 % share, growing at 15.64 % CAGR to 2034.

Top 5 Major Dominant Countries in the Independent Diagnostic Laboratories Application

• United States: Independent labs size ~USD 520 million with ~40 % share, CAGR 15.64 % to 2034.
• Germany: Size ~USD 155 million with ~12 % share, CAGR 15.64 % by 2034.
• United Kingdom: Size ~USD 115 million with ~9 % share, CAGR 15.64 % through 2034.
• Japan: Size ~USD 105 million with ~8 % share, CAGR 15.64 % to 2034.
• China: Size ~USD 90 million with ~7 % share, CAGR 15.64 % by 2034.

Cancer Research Institute: accounted for approximately 10 % of total test volume in 2023. In North America their share is about 8 %; Europe 10 %; Asia‑Pacific 12 %. These institutes perform roughly 15 % of CTC and PCA3 tests, and about 10 % of immunohistochemistry testing. They account for around 10 % of imaging‑based advanced diagnostics. PSA screening in research institutes forms only about 5 % of their total volume, as their emphasis lies on advanced assays. These institutes often pilot new tests, representing approximately 15 % of early‑use adoption in biomarker and liquid biopsy studies.

Cancer Research Institutes segment size is USD 776 million in 2025, with ~12 % share, growing at 15.64 % CAGR to 2034.

Top 5 Major Dominant Countries in the Cancer Research Institutes Application

• United States: Research institutes size ~USD 310 million with ~40 % share, CAGR 15.64 % to 2034.
• Germany: Size ~USD 93 million with ~12 % share, CAGR 15.64 % through 2034.
• United Kingdom: Size ~USD 78 million with ~10 % share, CAGR 15.64 % by 2034.
• Japan: Size ~USD 70 million with ~9 % share, CAGR 15.64 % through 2034.
• China: Size ~USD 62 million with ~8 % share, CAGR 15.64 % by 2034.

Others application segment size is USD 804 million in 2025, with ~13 % share, growing at 15.64 % CAGR to 2034.

Top 5 Major Dominant Countries in the Others Application

• United States: Others application size ~USD 325 million with ~40 % share, CAGR 15.64 % to 2034.
• Germany: Size ~USD 96 million with ~12 % share, 15.64 % CAGR through 2034.
• United Kingdom: Size ~USD 80 million with ~10 % share, CAGR 15.64 % to 2034.
• Japan: Size ~USD 73 million with ~9 % share, CAGR 15.64 % by 2034.
• China: Size ~USD 65 million with ~8 % share, CAGR 15.64 % to 2034.

Prostate Cancer Diagnostics Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

contributed approximately 46 % of global prostate cancer diagnostics test volume in 2024. In the USA in 2023, about 299 010 new prostate cancer diagnoses occurred with approximately 34 700 deaths. Confirmatory tests contributed to roughly 67 % of diagnostic volume, with preliminary screening at 33 %. PSA testing alone accounted for around 50 % of test procedures in the USA. Imaging and advanced tests constituted approximately 20 % of diagnostic mix in hospital associated labs. Hospital labs conducted about 70 % of diagnostic procedures; independent diagnostic labs held around 20 %; cancer research institutes around 10 %. CTC and PCA3 tests comprised a combined 8 % of test volume; immunohistochemistry about 12 %. At‑home PSA testing represented 5 % of screening. North America benefits from high awareness: 1 in 8 men lifetime risk, high median age of diagnosed patients above 65 in over 60 % of cases.

North America market size is USD 2 980 million in 2025, approximately 46 % share, growing at 15.64 % CAGR through 2034.

North America – Major Dominant Countries in the “Prostate Cancer Diagnostics Market”

• United States: Market size USD 2 320 million with ~78 % share of North America, CAGR 15.64 % through 2034.
• Canada: Market size USD 390 million with ~13 % share, CAGR 15.64 % to 2034.
• Mexico: Market size USD 180 million with ~6 % share, CAGR 15.64 % through 2034.
• Puerto Rico: Market size USD 60 million with ~2 % share, CAGR 15.64 % by 2034.
• Other North America: Market size USD 30 million with ~1 % share, CAGR 15.64 % through 2034.

EUROPE

held about 30 % share of global prostate cancer diagnostics volume in 2024. In countries like UK, Germany, France and Italy, PSA tests formed around 40 % of procedures. Confirmatory diagnostic tests made up approximately 67 % of test volume. CTC/PCA3 tests combined accounted for about 6 %, while immunohistochemistry represented around 9 %. Imaging and other advanced modalities accounted for roughly 35 % of diagnostic mix. Hospital associated labs conducted around 60 % of tests; independent labs 25 %; cancer research institutes 10 %; others 5 %. In UK, national screening programs detected approximately 268 490 new cases in 2022, which is around 9 % of global incidence. Approximately 80 % of those detected were prostatic adenocarcinoma. At‑home PSA adoption is under 3 % region‑wide.

Europe market size is USD 1 940 million in 2025, approximately 30 % share, growing at 15.64 % CAGR to 2034.

Europe – Major Dominant Countries in the “Prostate Cancer Diagnostics Market”

• Germany: Market size USD 540 million with ~28 % share of Europe, CAGR 15.64 % through 2034.
• United Kingdom: USD 390 million with ~20 % share, CAGR 15.64 % by 2034.
• France: USD 320 million with ~16 % share, CAGR 15.64 % to 2034.
• Italy: USD 260 million with ~13 % share, CAGR 15.64 % through 2034.
• Spain: USD 200 million with ~10 % share, CAGR 15.64 % by 2034.

ASIA-PACIFIC

contributed around 22 % of global prostate cancer diagnostics volume in 2024. PSA test usage in region was approximately 35 % of diagnostic mix, lower than North America and Europe. Confirmatory test volume remained at 67 %. CTC/PCA3 uptake was only about 4 %; immunohistochemistry near 5 %. Imaging and other tests made up around 45 %. Hospital associated labs performed about 55 % of procedures; independent labs 30 %; research institutes 12 %; others 3 %. Japan held the highest share in region, with geriatrics aged 65+ at 30.1 % of population in 2023 and rising prostate cancer incidence. Sinotau Pharmaceutical partnership in China introduced Flotufolastat 18F injection in late 2023. Government investment in India announced Rs 135 crore (~USD 17 million) for cancer hospitals in Assam. Screening coverage in country was under 40 % for men over 50. Asia‑Pacific remains under‑penetrated in biomarker diagnostics: PCA3/CTC at 4 % vs global 12 %. AI imaging adoption stands at 15 %.

Asia market size is USD 1 420 million in 2025, approximately 22 % share of global market, growing at 15.64 % CAGR by 2034.

Asia – Major Dominant Countries in the “Prostate Cancer Diagnostics Market”

• China: Market size USD 400 million with ~28 % share of Asia, CAGR 15.64 % to 2034.
• Japan: USD 310 million with ~22 % share, CAGR 15.64 % by 2034.
• India: USD 210 million with ~15 % share, CAGR 15.64 % through 2034.
• South Korea: USD 150 million with ~11 % share, CAGR 15.64 % to 2034.
• Australia: USD 120 million with ~8 % share, CAGR 15.64 % by 2034.

MIDDLE EAST & AFRICA

accounted for under 5 % of global diagnostic volumes in 2024. PSA usage in the region ranged between 30 % and 40 %. Confirmatory tests made up approximately 67 %. CTC/PCA3 adoption was below 3 %, immunohistochemistry about 4 %, others imaging about 55 %. Hospital labs conducted around 50 % of procedures; independent labs around 30 %; cancer research institutes about 15 %; others 5 %. Screening coverage for men aged above 50 remained under 35 % in many countries. Confirmatory biopsy procedures still dominate 67 % of diagnostic pathways. Imaging adoption is significant but limited to advanced centers, representing around 55 % of diagnostics. AI‑based imaging platforms are present in around 10 % of leading hospitals. Biomarker uptake for CTC or PCA3 is minimal due to regulatory and cost hurdles. Infrastructure gaps limit independent lab share.

Middle East & Africa market size is USD 324 million in 2025, approximately 5 % share, growing at 15.64 % CAGR to 2034.

Middle East and Africa – Major Dominant Countries in the “Prostate Cancer Diagnostics Market”

• Saudi Arabia: Market size USD 95 million with ~29 % share of region, CAGR 15.64 % to 2034.
• South Africa: USD 80 million with ~25 % share, CAGR 15.64 % by 2034.
• United Arab Emirates: USD 60 million with ~19 % share, CAGR 15.64 % through 2034.
• Egypt: USD 50 million with ~15 % share, CAGR 15.64 % to 2034.
• Nigeria: USD 39 million with ~12 % share, CAGR 15.64 % by 2034.

List of Top Prostate Cancer Diagnostics Companies

• Abbott Laboratories
• Caldera Health
• Myriad Genetics, Inc.
• Siemens Healthcare GmbH
• Hoffman-La Roche AG
• Myriad Genetics
• Genomic Health
• Gregor Diagnostics
• MDx Health
• OPKO Health, Inc
• Minomic
• Diagnolita
• Exosome Diagnostics

Abbott Laboratories – holds approximately 11 % share of U.S. PSA and reagent distribution volume.

Myriad Genetics, Inc. – holds roughly 9 % share of U.S. biomarker and PCA3 test volume.

Investment Analysis and Opportunities

Investment in prostate cancer diagnostic infrastructure saw government injection of approximately USD 9 million into HRSA‑funded health centres in August 2024. Research institutes increased funding by 12 % annually in biomarker development. The U.S. market, representing about 33 % of North American diagnostic volume, continues to attract investment in AI imaging platforms, adopted by approximately 20 % of major centres. Asia‑Pacific investments include Rs 135 crore (~USD 17 million) government support in India and partnerships such as Sinotau with Blue Earth Diagnostics in China introducing Flotufolastat 18F imaging in November 2023.

Private equity funding in diagnostics rose by around 10 % in 2024 for companies developing liquid biopsy and genomic platforms, with CTC and PCA3 tests comprising ~12 % of diagnostic volume. Independent diagnostic labs expanded network by ~5 % in North America and Europe, increasing test volume share from 20 % to 25 %. Cancer research institutes pilot approximately 15 % of emerging assays. Opportunities include scaling biomarker assay adoption in Asia‑Pacific (currently 4 %) and Middle East & Africa (under 3 %). Investments in AI imaging, rising to 20 % centre adoption globally, present opportunity to reduce biopsy reliance by up to 15 %.

New Product Development

Innovation in prostate cancer diagnostics includes launch of Flotufolastat (18F) Injection in China in November 2023 by Sinotau in partnership with Blue Earth Diagnostics, improving imaging-based detection volumes. GE HealthCare introduced AI‑enabled Prostate Volume Assist software in March 2024 adopted by around 20 % of diagnostic centres in North America and Europe. LynxDx introduced MyProstateScore 2.0—a urine‑based non‑invasive biomarker assay—in February 2023, with adoption by research institutes and independent labs (~10 % of labs in North America).

Myriad Genetics in May 2022 launched a comprehensive suite for detection of prostate cancers, representing approximately 9 % of U.S. biomarker test volume. Hospital labs implementing multiparametric MRI expanded MRI usage to about 15 % of imaging test volume by 2024. Liquid biopsy workflows integrating CTC assays increased application in monitoring protocols to nearly 12 % of test volume.

Five Recent Developments

• LynxDx introduced MyProstateScore 2.0 urine assay in February 2023, now used by ~10 % of North American labs.
• Flotufolastat (18F) Imaging launched in China November 2023, expanding imaging options in Asia‑Pacific diagnostic volume share.
• GE HealthCare launched Prostate Volume Assist AI imaging software in March 2024, adopted by ~20 % of advanced centres in North America/Europe.
• Sinotau Pharmaceutical partnership with Blue Earth Diagnostics in late 2023 increased diagnostic imaging uptake in China to ~3 % regional share.
• Myriad Genetics suite introduced May 2022 grew PCA3 and biomarker testing to ~9 % of U.S. diagnostic volumes by end‑2023.

Report Coverage of Prostate Cancer Diagnostics Market

This Prostate Cancer Diagnostics Market Report delivers coverage of worldwide diagnostics activity, including test type segmentation (PSA Tests, CTC Tests, Immunohistochemistry, PCA3 Tests, Others), application categories (Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes, Others), geography across North America, Europe, Asia‑Pacific, Middle East & Africa, and company profiles. Coverage includes annual test volumes by type, with confirmatory test volumes at approximately 67 % share and preliminary screening at 33 %. Regional market share data includes North America at 46 %, Europe at 30 %,

Asia‑Pacific at 22 %, and Middle East & Africa under 5 %. It features USA-specific data, including approximately 299 010 new cases and 34 700 deaths in 2023. The report includes segmentation figures: PSA tests ~45 % globally; CTC/PCA3 ~12 %; IHC ~10 %; others ~33 %. End‑use coverage shows hospital labs holding 65 %, independent labs 25 %, cancer institutes 10 %. Coverage extends to product development updates such as Flotufolastat, Prostate Volume Assist AI software, MyProstateScore 2.0. Investment data includes government funding of USD 9 million in HRSA centers 2024, Rs 135 crore investment in cancer infrastructure in India 2023.

Prostate Cancer Diagnostics Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 7470.57 Million in 2026
Market Size Value By	USD 27617.18 Million by 2035
Growth Rate	CAGR of 15.64% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : PSA Tests CTC Tests Immunohistochemistry PCA3 Tests Others By Application : Hospital Associated Labs Independent Diagnostic Laboratories Cancer Research Institutes Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample